Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Capricor Therapeutics plans to apply for FDA approval for its DMD cell therapy, deramiocel, by the end of 2024.

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

One doctor spoke out warning that women may be getting misdiagnosed with a common condition when they may actually be ...

Cancer Research UK hailed the shift as the biggest improvement in cervical cancer treatment in more than 20 years ...

Trump and Harris Both Like a Child Tax Credit, but With Different Aims Kamala Harris’s campaign is pushing a version of the credit intended to fight child poverty, while Donald Trump sees the ...